Keratoacanthoma
☆ An den 2022 Stiftung Warentest Resultater aus Däitschland war d'Zefriddenheet vum Konsument mam ModelDerm nëmme liicht manner wéi mat bezuelte Telemedizin Konsultatiounen.
Typesch Keratoacanthoma
References
Keratoacanthoma (KA) ass en dacks Hauttumor bekannt fir säi séiere Wuesstum a Potenzial fir eleng zréckzekommen. Et geschitt typesch an eeler, fair-skinned Männer mat enger Geschicht vun Sonn Schued. Wärend chirurgesch Entfernung mat Ausschnëtter oder Mohs mikrografescher Chirurgie déi üblech Behandlung ass, ginn et verschidden aner Therapieoptiounen verfügbar.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) ass e Low-grade Tumor deen a bestëmmte Drüsen an der Haut ufänkt an ähnlech wéi squamous cell carcinoma (SCC) ënner engem Mikroskop ausgesäit. Et gëtt dauernd Debatt iwwer ob KA soll als Form vun invasiv SCC klasséiert ginn.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) ass déi zweet heefegst Aart vu Kriibs bei Leit, besonnesch bei eeler Leit. Chirurgie gëtt typesch benotzt fir cSCC ze behandelen, awer fir e puer Patienten déi keng Chirurgie kënnen hunn oder net wielen, kënnen aner Optiounen wéi intralesional Behandlungen berücksichtegt ginn. Traditionell intralesional Behandlungen (methotrexate or 5-fluorouracil) goufen benotzt, awer et gëtt lafend Fuerschung iwwer nei Approche wéi intralesional Immuntherapie an onkolytesch Virotherapie. Hei wäerte mir verschidde intralesional Behandlungen fir cSCC kucken, rangéiert vu klassesche Methoden bis modernste Strategien.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Ënnert dem Mikroskop gläicht keratoacanthoma ganz no squamous Zellkarzinom. Wärend e puer Pathologen keratoacanthoma als eng ënnerschiddlech Entitéit klassifizéieren an net eng Malignitéit, ongeféier 6% vun de klineschen an histologeschen keratoacanthoma fortschrëtt sech op invasiv an aggressiv Plateauzellkriibs.
○ Diagnos a Behandlung
#Dermoscopy
#Skin biopsy